InflaR: Positive Data from Phase II Vasculitis Study

 

• Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of care
  

• Use of vilobelimab instead of glucocorticoids led to a substantially lower observed glucocorticoid toxicity

• Vilobelimab demonstrated a good safety and tolerability profile; vilobelimab only treatment arm had lowest number of reported treatment emergent adverse events

https://finance.yahoo.com/news/inflarx-announces-positive-data-phase-123000367.html